Celltrion confirms neutralising potency against emerging SARS-CoV-2 variants with anti-COVID-19 monoclonal antibody treatment regdanvimab (CT-P59)

Celltrion Group today announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed neutralising potency against emerging variants first identified in New York (B.1.526), Nigeria (B.1.525) and …